Zobrazeno 91 - 100
of 205
pro vyhledávání: '"Edward Kerwin"'
Autor:
Christy Cappelletti, Gary T. Ferguson, Edward Kerwin, Elizabeth A. Duncan, Alberto Papi, Antonio Anzueto, Paul Dorinsky, Jack Nyberg
Publikováno v:
Clinical Problems.
Objective: To assess the efficacy and safety of BFF MDI vs budesonide (BD) MDI, formoterol fumarate dihydrate (FF) MDI and Symbicort® Turbuhaler® (BUD/FORM dry powder inhaler [DPI]) in symptomatic subjects with moderate-to-very severe COPD (NCT0276
Autor:
Edward Kerwin, Donald A. Mahler, Francesco Patalano, Angel FowlerTaylor, Donald Banerji, Samopriyo Maitra, Chau Thach, Tim Ayers, Mark Lloyd
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 192:1068-1079
Current Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy recommends the combination of two long-acting bronchodilators of different pharmacologic classes for the management of chronic obstructive pulmonary disease (COPD) if symp
Publikováno v:
COPD: Journal of Chronic Obstructive Pulmonary Disease. 13:167-175
Patients' preference is an important factor in selecting an inhaler treatment for COPD. The DISKUS® dry powder inhaler (DPI), which has been available to deliver several COPD medications for a decade, and the ELLIPTA® DPI, developed for the deliver
Publikováno v:
COPD
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Combinations of drugs with distinct and complementary mechanisms of action may offer improved efficacy in the treatment of chronic obstructive pulmonary disease (COPD). In two 12-week, double-blind, parallel-group studies, patients with COPD were ran
Publikováno v:
Respiratory Medicine. 109(9):1155-1163
ObjectiveThe aim of these studies (NCT01957163; NCT02119286) was to evaluate the efficacy and safety of umeclidinium (UMEC 62.5 μg and 125 μg) added to fluticasone furoate/vilanterol (FF/VI, 100/25 μg) in chronic obstructive pulmonary disease (COP
Autor:
Kari C. Nadeau, Anthony R. Ricci, Rosalba E. Puente, Karin S. Coyne, Acklema Mohammad, Patricia H. Stewart, Peggy Rubio O’Connor, Kevin R. Murphy, Nathan James Lesch, Pulin P. Patel, Russell Settipane, Reneé Stadtler, David C. Mares, Jeffrey Rehm, James M. Eudicone, Rabinder Sidhu, Weily Soong, Christine Czajkowski, Allison Ramsey, Amanda L. Michaud, Lori A. Bowers, Xavier Soler, Theodore E. Kelbel, Andrew M. Smith, S. Shahzad Mustafa, Ewa Rakowski, Martha V. White, Raji M. Ayinla, Robert A. Wise, Bruce M. Schnapf, Maxcie M. Sikora, Brett V. Kettelhut, Sherif Al-Farra, Jason M. Bellak, Tabarak Qureshi, Vipin Jain, Adam T. Cherry, Danuel Hamlin, Jennifer Trevor, Taiwen Chen, Lindsay D. Humes, Joseph Dominic Fisher, Neal Jain, Sonia N. Bains, James E. Pearl, Florence Ida Hsu, Patricia L. Luthin, Ziad R. Mattar, Chitra R. Natalie, Edward Schuman, Kartik Shenoy, Susan Estrella-Eades, Mitchell Smith, Gary N. Gross, Ileen Gilbert, Cara Kraft, Francis J. Averill, William McCann, Bradley E. Chipps, Howard J. Lee, J. Paul Cook, Leslie A. Stefanowicz, B. Steele Rolston, Jonathan R. Romeo, R. Sharon Chinthrajah, Sami Abdul Jawad, Brian Stone, Eugene R. Bleecker, Daisy Arce, David G. Hill, John G. Southard, Justin Greiwe, Jonathan Ilowite, Christine Anderson, Joann Blessing-Moore, Jorge Manuel Mercado, Amy Palmer, James P. Krainson, Jill Hanson, Sarah Villegas, Sandra G. Adams, Ellen R. Sher, Karen L. Gregory, Thomas P. Miller, Hassan Nasir, David Pham, Neil Parikh, Bryan Krajicek, John Gedell, Gale Harding, Devi K. Jhaveri, Steven L. Wise, Salim Surani, Maeve Edel O’Connor, Alan Gaines, Franco Barsanti, Andrew S. Kim, Matthew C. Wilson, Andrew A. White, David A. Beuther, Javier Perez-Fernandez, Igor Barjaktarevic, Melvin Lee Morganroth, Matthew Hegewald, Shyamsunder Subramanian, H. Gandhi, Jodi H. Biller, G. Gilbert Head, Da-Wei Liao, Nicholas L. Hartog, Carly Hopkins, Brian D. Modena, Richard A. Wachs, Rory L. Duplantier, Edward Kerwin, Robert S. Zeiger, Laren D. Tan, Aaron K. Kobernick, Randall Brown, Susan M. Smith, Jon Eric Chancellor, Alan Fein, Peter Schochet, Geoffrey Chupp, Mario F. Perez, Ronald C. Balkissoon, Derek K. Johnson, Nabeel Farooqui, Steven G. Kelsen, Diego J. Maselli, Jessica Freyer Most, Pinkus Goldberg, Deborah Simmons
Publikováno v:
The Journal of Allergy and Clinical Immunology: In Practice. 8:2263-2274.e5
Background Asthma exacerbation risk increases with worsening asthma control. Prevailing numerical control tools evaluate only current symptom impairment despite the importance of also assessing risk based on exacerbation history. An easy-to-use quest
Autor:
Maggie Tabberer, Huib A. M. Kerstjens, Steven Pascoe, Louis-Philippe Boulet, Zelie Bailes, Neal Sule, Dawn Edwards, Guy Peachey, Laurie Lee, Neil Barnes, Ian D. Pavord, Andrew Fowler, Robert A. Nathan, Edward Kerwin, Nicola A. Hanania
Publikováno v:
Journal of Allergy and Clinical Immunology. 145:AB241
Autor:
Frances Gardiner, Dawn Edwards, Huib A. M. Kerstjens, Neal Sule, Laurie Lee, Edward Kerwin, Nicola A. Hanania, Neil Barnes, Guy Peachey, Steven Pascoe, Zelie Bailes, Ian D. Pavord, Andrew Fowler
Publikováno v:
Journal of Allergy and Clinical Immunology. 145:AB24
Autor:
François Maltais, Claus Vogelmeier, Paul W. Jones, Chris Compton, Ian Naya, David A. Lipson, Leif Bjermer, Isabelle Boucot, Neil Barnes, Lee Tombs, Edward Kerwin
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 14 (2020)
Rationale: Symptom relief is a key treatment goal in patients with chronic obstructive pulmonary disease (COPD). However, there are limited data available on the response to bronchodilator therapy in patients at low risk of exacerbations with differe
Autor:
Paul W. Jones, Ian Naya, Edward Kerwin, Isabelle Boucot, David A. Lipson, François Maltais, Tom Keeley, Lee Tombs, Claus Vogelmeier, Leif Bjermer
Publikováno v:
Therapeutic Advances in Respiratory Disease. 14:175346662092694
Background: In chronic obstructive pulmonary disease (COPD), both the time needed for patients to gain symptom improvement with long-acting bronchodilator therapy and whether an early response is predictive of a sustained response is unknown. This st